Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials.

While the change from baseline in the percentage of days without difficulty bringing up phlegm was numerically higher with aclidinium (7.7%) and tiotropium (4.8%) compared with placebo (2.0%), the differences between the active treatments and placebo did not reach statistical significance (p=0.100 for aclidinium and p=0.425 for tiotropium).

also in 111,027 other papers